**Specifications Table**TableSubject area*Analytical Chemistry*More specific subject area*Vitamin D and supercritical fluid chromatography*Type of data*ChromatogramsMass spectraFigures*How data was acquired*Method development for the separation and analysis of vitamin D metabolites was performed on Waters ACQUITY UPC*^*2*^*and Waters ACQUITY UPLC coupled to a Waters Xevo TQ-MS mass spectrometer.*Data format*Raw and analyzed*Experimental factors*Working standards of vitamin D were prepared in methanol for UPSFC-MS/MS analysis and methanol/water (50/50%) for UPLC-MS/MS analysis.Derivatization of vitamin D metabolites was performed using 4-Phenyl-1,2,4-triazole-3,5-dione (PTAD) and 4-\[2-(3,4-Dihydro-6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl\]-3H-1,2,4-triazole-3,5(4H)-dione (DMEQ-TAD).*Experimental features*Comparison of vitamin D metabolite elution and separation between UPSFC and UPLC.Optimization of UPSFC parameters for separation and detection of vitamin D.*Data source location*Birmingham, United Kingdom.*Data accessibility*Data is with this article*Related research article*C. Jenkinson, A Taylor, K. Storbeck, M. Hewison. Analysis of multiple vitamin D metabolites by ultra performance supercritical fluid chromatography-tandem mass spectrometry (UPSFC-MS/MS). Journal of Chromatography B. 2017.*, 1087--1088 (2018), pp.43--48. doi: 10.1016/j.jchromb.2018.04.025

**Value of the data**●The direct comparison between optimized UPSFC and UPLC methods could provide an insight into which separation technique is best suited for routine analysis of vitamin D and other similar small molecules.●The data presented from the UPSFC-MS/MS method development and optimization provides a benchmark for future method development approaches using this platform.●The analytical methods presented incorporate the analysis of multiple active and inactive vitamin D forms across the metabolic pathway. This data will be valuable for clinical assessments in vitamin D health and disease.

1. Data {#s0005}
=======

1.1. Elution order and chromatography comparison between UPSFC-MS/MS and UPLC-MS/MS {#s0010}
-----------------------------------------------------------------------------------

The chromatograms in [Section 1.1](#s0010){ref-type="sec"} compare the chromatography of UPSFC-MS/MS and UPLC-MS/MS for measuring multiple vitamin D metabolites; vitamin D3, vitamin D2, 25-hydroxyvitamin D3 (25OHD3), 25OHD2, 24OHD2, 3-epi-25OHD3, 1α,25-dihydroxyvitamin D3 (1α,25(OH)~2~D3), 23,25(OH)~2~D3 and 24,25(OH)~2~D3 ([Fig. 1](#f0005){ref-type="fig"}). The elution order of vitamin D analytes is compared between UPSFC and UPLC in [Fig. 2](#f0010){ref-type="fig"}.Fig. 1Chromatogram of vitamin D analytes on UPSFC and UPLC, separated using a Lux Cellulose-2 chiral column.Fig. 1Fig. 2Comparison in elution order of vitamin D analytes on UPSFC and UPLC.Fig. 2

1.2. Optimization of mass spectrometry conditions {#s0015}
-------------------------------------------------

The data in [Section 2](#s0030){ref-type="sec"} was obtained during the method development and optimization of the UPSFC-MS/MS method. Section 2.1 presents data from the optimization of multiple reaction mode (MRM) parameters using 1α,25(OH)~2~D3 derivatized with DMEQ-TAD as an example. The mass spectra from full scan and daughter scan of m/z 762.6 \> 247.5 are shown in [Fig. 3](#f0015){ref-type="fig"}. The signal intensity of 1α,25(OH)~2~D3 DMEQ-TAD is compared with a range of cone voltage and collision energies in [Fig. 4](#f0020){ref-type="fig"} to determine the optimal values.Fig. 3Mass spectrum of full scan and daughter scans of 1α,25(OH)~2~D3 following derivatization with DMEQ-TAD.Fig. 3Fig. 4Signal intensity (area) of 1α,25(OH)~2~D3-DMEQ TAD at a range of collision energy (25--60) and cone voltage (25--50) values.Fig. 4

1.3. Optimization of UPSFC column conditions {#s0020}
--------------------------------------------

The chromatograms and figures in section 2.2 relate to the optimization of UPSFC column screening and selection for optimized separation of vitamin D metabolites. The chromatograms displayed in [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"} compare different column chemistries and column size to optimize vitamin D separation by UPSFC.Fig. 5Column screening on UPSFC to separate 25OHD3 and 3-epi-25OHD3. Both analytes have a mass to charge (*m/z*) of 401.6.Fig. 5Fig. 6Chromatogram of vitamin D analytes on Lux Cellulose-2 chiral columns with different dimensions: 100 × 2 mm and 150 × 3 mm.Fig. 6

1.4. Optimization of UPSFC method parameters {#s0025}
--------------------------------------------

The chromatographs and figures in section 2.3 are outputs from the optimization of UPSFC parameters for vitamin D analysis. The chromatograms compare the separation and signal intensity of 25OHD3 and 3-epi-25OHD3 with increasing injection volume and atmospheric back pressure regulator (ABPR) in [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, respectively. The signal intensity of vitamin D analytes is compared for the optimization of the inlet flow rate, ABPR, column temperature and solvent for sample reconstitution in [Fig. 9](#f0045){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"}, [Fig. 11](#f0055){ref-type="fig"} respectively ([Fig. 12](#f0060){ref-type="fig"}).Fig. 7Separation and signal intensity (area) of 25OHD3 and 3-epi-25OHD3 with increasing sample injection volume (2--7 µL) using a 150 × 3 mm Lux Cellulose-2 chiral column.Fig. 7Fig. 8Elution of 25OHD3 and 3-epi-25OHD3 with increasing ABPR (1500--2000 psi) using a 150 × 3 mm Lux Cellulose-2 chiral column.Fig. 8Fig. 9Analyte areas of vitamin D metabolites with increasing split flow rate (0.08--0.9 mL/min) containing methanol 0.1% formic acid.Fig. 9Fig. 10Analyte areas of vitamin D metabolites with increasing ABPR (1500-200 psi).Fig. 10Fig. 11Analyte areas of vitamin D metabolites with increasing column temperature (20--50 °C).Fig. 11Fig. 12Analyte areas with different solvents used for sample reconstitution.Fig. 12

2. Experimental design, materials, and methods {#s0030}
==============================================

The sample preparation, UPSFC-MS/MS and UPLC-MS/MS methodologies for the data presented here have been previously described and cited [@bib1]. The DMEQ-TAD sample preparation method is described previously [@bib2].
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